All Stories

  1. Soybean (Glycine max) Is Able to Absorb, Metabolize and Accumulate Fenbendazole in All Organs Including Beans
  2. Leaves and Fruits Preparations of Pistacia lentiscus L.: A Review on the Ethnopharmacological Uses and Implications in Inflammation and Infection
  3. <em>Pistacia lentiscus</em>: From Phytopharmacology to Scientific Explanations on Its Anti-Inflammatory and Antimicrobial Capacity
  4. The Identification of Metabolites and Effects of Albendazole in Alfalfa (Medicago sativa)
  5. The Uptake of Ivermectin and Its Effects in Roots, Leaves and Seeds of Soybean (Glycine max)
  6. The Modulation of Phase II Drug-Metabolizing Enzymes in Proliferating and Differentiated CaCo-2 Cells by Hop-Derived Prenylflavonoids
  7. The Pharmaceutical Ability of Pistacia lentiscus L. Leaves Essential Oil Against Periodontal Bacteria and Candida sp. and Its Anti-Inflammatory Potential
  8. The Pharmaceutical Ability of <em>Pistacia lentiscus</em> L. Leaves Essential Oil against Periodontal Bacteria and Candida sp. and Its Anti-inflammatory Potential
  9. Ivermectin biotransformation and impact on transcriptome in Arabidopsis thaliana
  10. Ivermectin environmental impact: Excretion profile in sheep and phytotoxic effect in Sinapis alba
  11. Biotransformation of flubendazole and fenbendazole and their effects in the ribwort plantain (Plantago lanceolata)
  12. The inhibitory effects of β-caryophyllene, β-caryophyllene oxide and α-humulene on the activities of the main drug-metabolizing enzymes in rat and human liver in vitro
  13. Sulforaphane Alters β-Naphthoflavone-Induced Changes in Activity and Expression of Drug-Metabolizing Enzymes in Rat Hepatocytes
  14. Evaluation of drug uptake and deactivation in plant: Fate of albendazole in ribwort plantain (Plantago laceolata) cells and regenerants
  15. Design, Synthesis, and Biological Evaluation of Isothiosemicarbazones with Antimycobacterial Activity
  16. Nerolidol and Farnesol Inhibit Some Cytochrome P450 Activities but Did Not Affect Other Xenobiotic-Metabolizing Enzymes in Rat and Human Hepatic Subcellular Fractions
  17. Effect of Green Tea Extract-Enriched Diets on Insulin and Leptin Levels, Oxidative Stress Parameters and Antioxidant Enzymes Activities in Obese Mice
  18. Catechins Variously Affect Activities of Conjugation Enzymes in Proliferating and Differentiated Caco-2 Cells
  19. Metabolic pathways of benzimidazole anthelmintics in harebell (Campanula rotundifolia)
  20. Albendazole in environment: faecal concentrations in lambs and impact on lower development stages of helminths and seed germination
  21. Cranberry extract–enriched diets increase NAD(P)H:quinone oxidoreductase and catalase activities in obese but not in nonobese mice
  22. The Influence of Sesquiterpenes from Myrica rubra on the Antiproliferative and Pro-Oxidative Effects of Doxorubicin and Its Accumulation in Cancer Cells
  23. Metabolism of drugs and other xenobiotics in giant liver fluke (Fascioloides magna)
  24. Reliable reference gene selection for quantitative real time PCR in Haemonchus contortus
  25. Comparison of biotransformation and efficacy of aminoacetonitrile anthelmintics in vitro
  26. Effect of oral administration of green tea extract in various dosage schemes on oxidative stress status of mice in vivo
  27. Influence of diet supplementation with green tea extract on drug-metabolizing enzymes in a mouse model of monosodium glutamate-induced obesity
  28. Monepantel induces hepatic cytochromes p450 in sheep in vitro and in vivo
  29. Drug-Metabolizing and Antioxidant Enzymes in Monosodium L-Glutamate Obese Mice
  30. Biotransformation of anthelmintics in tapeworm Moniezia expansa
  31. Characterization of Tetratricopeptide Repeat-Like Proteins in Francisella tularensis and Identification of a Novel Locus Required for Virulence
  32. Effect of Standardized Cranberry Extract on the Activity and Expression of Selected Biotransformation Enzymes in Rat Liver and Intestine
  33. Effect of defined green tea extract in various dosage schemes on drug-metabolizing enzymes in mice in vivo
  34. Metabolic pathways of anthelmintic drug monepantel in sheep and in its parasite (Haemonchus contortus)
  35. Reference Genes for Real-Time PCR Quantification of Messenger RNAs and MicroRNAs in Mouse Model of Obesity
  36. Francisella tularensis subsp. holarctica DsbA homologue: a thioredoxin-like protein with chaperone function
  37. Biotransformation of albendazole and activities of selected detoxification enzymes in Haemonchus contortus strains susceptible and resistant to anthelmintics
  38. Biotransformation of benzimidazole anthelmintics in reed (Phragmites australis) as a potential tool for their detoxification in environment
  39. Analytical power of LLE–HPLC–PDA–MS/MS in drug metabolism studies: Identification of new nabumetone metabolites
  40. Inhibitory effect of anthocyanidins on hepatic glutathione S-transferase, UDP-glucuronosyltransferase and carbonyl reductase activities in rat and human
  41. Age-Related Changes in Hepatic Activity and Expression of Detoxification Enzymes in Male Rats
  42. Investigation of the metabolism of monepantel in ovine hepatocytes by UHPLC/MS/MS
  43. The metabolic fate of ivermectin in host (Ovis aries) and parasite (Haemonchus contortus)
  44. Import and efflux of flubendazole in Haemonchus contortus strains susceptible and resistant to anthelmintics
  45. The metabolism of flubendazole and the activities of selected biotransformation enzymes in Haemonchus contortus strains susceptible and resistant to anthelmintics
  46. The inability of tapeworm Hymenolepis diminuta and fluke Dicrocoelium dendriticum to metabolize praziquantel
  47. The activity of drug-metabolizing enzymes and the biotransformation of selected anthelmintics in the model tapeworm Hymenolepis diminuta
  48. High-performance liquid chromatographic determination of tiapride and its phase I metabolite in blood plasma using tandem UV photodiode-array and fluorescence detection
  49. The transport of albendazole and albendazole sulphoxide in the lancet fluke (Dicrocoelium dendriticum)
  50. The effects of flubendazole and its metabolites on the larval development of Haemonchus contortus (Nematoda: Trichostrongylidae): an in vitro study
  51. Effect of Flubendazole on Biotransformation Enzymes Activities in Haemonchus contortus~!2010-03-18~!2010-06-16~!2010-08-07~!
  52. In vitrooxidative metabolism of xenobiotics in the lancet fluke (Dicrocoelium dendriticum) and the effects of albendazole and albendazole sulphoxideex vivo
  53. Activities of biotransformation enzymes and flubendazole metabolism in lambs (Ovis aries): effect of gender and flubendazole therapy
  54. Flubendazole metabolism and biotransformation enzymes activities in healthy sheep and sheep with haemonchosis
  55. Pharmacokinetics of flubendazole and its metabolites in lambs and adult sheep (Ovis aries)
  56. Liquid chromatography/mass spectrometric identification of benzimidazole anthelminthics metabolites formed ex vivo by Dicrocoelium dendriticum
  57. The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells
  58. Phase I biotransformation of albendazole in lancet fluke (Dicrocoelium dendriticum)
  59. Characterization of metabolites of sibutramine in primary cultures of rat hepatocytes by liquid chromatography–ion trap mass spectrometry
  60. Sensitive chiral high-performance liquid chromatographic determination of anthelmintic flubendazole and its phase I metabolites in blood plasma using UV photodiode-array and fluorescence detection
  61. LC with Fluorimetric Detection for Sensitive Analysis of Reduced Flubendazole in Biological Samples
  62. LC–MS–MS identification of albendazole and flubendazole metabolites formed ex vivo by Haemonchus contortus
  63. Biotransformation of flubendazole and selected model xenobiotics in Haemonchus contortus
  64. Modulation of Porcine (Sus scrofa domestica) and Pheasant (Phasianus colchicus) Carbonyl Reducing Enzymes by Anthelmintic Therapy with Flubendazole
  65. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man
  66. Activities of biotransformation enzymes in pheasant (Phasianus colchicus) and their modulation by in vivo administration of mebendazole and flubendazole
  67. Achiral and chiral high-performance liquid chromatographic determination of flubendazole and its metabolites in biomatrices using UV photodiode-array and mass spectrometric detection
  68. Mouflon (Ovis musimon) dicrocoeliosis: Effects of parasitosis on the activities of biotransformation enzymes and albendazole metabolism in liver
  69. Modulation of porcine biotransformation enzymes by anthelmintic therapy with fenbendazole and flubendazole
  70. The effects of flubendazole and mebendazole on cytochromes P4501A in pheasant hepatocytes
  71. Liver microsomal biotransformation of albendazole in deer, cattle, sheep and pig and some related wild breeds
  72. Albendazole repeated administration induces cytochromes P4501A and accelerates albendazole deactivation in mouflon (Ovis musimon)
  73. Use of chiral liquid chromatography for the evaluation of stereospecificity in the carbonyl reduction of potential benzo[c]fluorene antineoplastics benfluron and dimefluron in various species
  74. The stereoselective biotransformation of the anti-obesity drug sibutramine in rat liver microsomes and in primary cultures of rat hepatocytes
  75. Chiral Inversion of Drugs: Coincidence or Principle?
  76. The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11β-hydroxysteroid dehydrogenase type 1
  77. The effects of fenbendazole, flubendazole and mebendazole on activities of hepatic cytochromes P450 in pig
  78. Characterization of enzymes responsible for biotransformation of the new antileukotrienic drug quinlukast in rat liver microsomes and in primary cultures of rat hepatocytes
  79. Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep
  80. The Phase I Biotransformation of the Potential Antileukotrienic Drug Quinlukast in Rat Microsomes and Hepatocytes
  81. Stereospecificity of flobufen metabolism in guinea pigs in vitro and in vivo: Phase I of biotransformation
  82. Inter-species comparisons of hepatic cytochrome P450 enzyme levels in male ruminants
  83. Stereospecific biotransformation of albendazole in mouflon and rat‐isolated hepatocytes
  84. Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues
  85. Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11β-hydroxysteroid dehydrogenase type 1
  86. Chiral aspects of metabolism of antiinflammatory drug flobufen in human hepatocytes
  87. Reduction of flobufen in pig hepatocytes: Effect of pig breed (domestic, wild) and castration
  88. Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9-dimethoxybenfluron in human in vitro
  89. Effect of ivermectin on activities of cytochrome P450 isoenzymes in mouflon (Ovis musimon) and fallow deer (Dama dama)
  90. Biotransformation of flobufen enantiomers in ruminant hepatocytes and subcellular fractions
  91. Stereospecificity and stereoselectivity of flobufen metabolic profile in male rats in vitro and in vivo: Phase I of biotransformation
  92. Effect of substituents on microsomal reduction of benzo(c)fluorene N-oxides
  93. Reduction of the Potential Anticancer Drug Oracin in the Rat Liver In-vitro
  94. Activity, stereospecificity, and stereoselectivity of microsomal enzymes in dependence on storage and freezing of rat liver samples
  95. A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomersin vitro in rat and guinea pig
  96. Sex differences in stereospecificity of oracin reductases in ratin vitro andin vivo
  97. Stereoselective pharmacokinetics of flobufen in rats
  98. High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin
  99. High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracine